WHO Experts Review the Severe Side Effects Data of Sinovac, Commented "Low Credibility" for Elderly
WHO experts indicated 5 May that the Chinese Sinovac for COVID-19 has protection to adults who are under 60. However, there is a lack of data on the risk of serious side effects from vaccines, with “low credibility” for patients over aged 60 and with chronic illnesses. The expert group even referred to the severe side effect data of Sinovac on the elderly and patients with chronic illness as “very low” credibility.
The Strategic Advisory Group of Experts on Immunization (SAGE) in WHO evaluated the Phase 3 clinical test data of Sinovac in China, Brazil, Indonesia, Turkey, and Chile. They are very confident about the effectiveness of two doses of Sinovac in preventing adults aged 18-59, moderately confident about the severe side effect data on adults aged 59 years or younger. However, for those aged 60 years or older and patients with chronic diseases, the risk data of patients with severe side effects after vaccination is classified as “low credibility”, which means that the test data of Sinovac cannot determine the risks of serious side effects of Sinovac on the elderly and patients.
Source: Stand News #May06
https://bit.ly/3tKkLl3
#WHO #Vaccine #SAGE #COVID19 #China #Sinovac #Brazil #Indonesia #Turkey #Chile #Credibility #Phase3ClinicalTest
WHO experts indicated 5 May that the Chinese Sinovac for COVID-19 has protection to adults who are under 60. However, there is a lack of data on the risk of serious side effects from vaccines, with “low credibility” for patients over aged 60 and with chronic illnesses. The expert group even referred to the severe side effect data of Sinovac on the elderly and patients with chronic illness as “very low” credibility.
The Strategic Advisory Group of Experts on Immunization (SAGE) in WHO evaluated the Phase 3 clinical test data of Sinovac in China, Brazil, Indonesia, Turkey, and Chile. They are very confident about the effectiveness of two doses of Sinovac in preventing adults aged 18-59, moderately confident about the severe side effect data on adults aged 59 years or younger. However, for those aged 60 years or older and patients with chronic diseases, the risk data of patients with severe side effects after vaccination is classified as “low credibility”, which means that the test data of Sinovac cannot determine the risks of serious side effects of Sinovac on the elderly and patients.
Source: Stand News #May06
https://bit.ly/3tKkLl3
#WHO #Vaccine #SAGE #COVID19 #China #Sinovac #Brazil #Indonesia #Turkey #Chile #Credibility #Phase3ClinicalTest